Under the microscope: Improving hit discovery efficiency at Europe´s leading screening centre
Steven van Helden, Chief Technology Officer at Pivot Park Screening Centre (PPSC), relies on efficient microplate readers for effective hit discovery.
List view / Grid view
Articles
Genomic medicine: cracking genomes to cure ‘incurable’ diseases
We are on the precipice of realising the true potential of genomics studies. Following completion of the Human Genome Project six years ago, huge strides have been made in understanding how the genome works, shedding light on disease pathogenesis and forging therapeutic efforts. In this article, Pushpanathan Muthuirulan explains how…
Training and development in flow cytometry and other core technologies
There is still much to be done regarding how training is delivered and monitored in core technologies such as flow cytometry. Here, Derek Davies outlines the approaches his team at The Francis Crick Institute are taking to train users of such technologies to ensure quality data is obtained and best…
Hitting the target – utilising recombinant antibodies for viral research
Having worked in antibody research for over 20 years, Gary McLean has seen how the industry has progressed and understands the potential that antibodies have in the future of medicine. Nikki Withers hears how the focus has shifted from discovery to genetic sequence manipulation and how this can be applied…
Evaluation of therapeutic antibody discovery technologies
Protein therapeutics are a major class of biopharmaceuticals and monoclonal antibodies (mAbs) rule this domain. In this article, Dr Nancy Lopez-Anton outlines the key technologies employed in this important therapeutic discovery area; how they have evolved and what obstacles must be navigated to ensure future success.
Expert view: What role do connected pipettes play in the lab of the future?
As research moves forward at a rapid pace and data is being generated in larger quantities than ever before, one problem the scientific community faces is reproducibility.
Integrating drug discovery R&D
Pharmaceutical companies are under increasing pressure to get novel drugs to market as quickly as possible. Here, Sheraz Gul discusses how integrating processes could help streamline drug discovery in the future.
Expert view: Bio-Rad’s comprehensive genomics portfolio provides answers for every problem
Over three decades, Bio-Rad has built a broad genomics portfolio that touches on nearly every area of life science.
Getting connected – the key to solving the reproducibility problem?
As technology advances and scientific research progresses at a rapid pace, data is being generated in ever-larger quantities. Even with the forward strides in technology and advances in data processing, a common problem widely acknowledged by the scientific community is that of reproducibility. In this article, Matjaz Hren discusses the…
Expert view: Opportunities in flow cytometry
New therapies that direct the immune system to identify and destroy cancer cells, such as CAR-T and immune checkpoint inhibitors, have revolutionised cancer treatment.
Expert view: The importance of accurate synthetic DNA fragments
Innovations in synthesis technology and gene synthesis have become a powerful and valuable means of obtaining genetic material.
Expert view: Advancing antibody discovery with picodroplet technology
It is predicted that there will be 70 new monoclonal antibody (mAb) biotherapeutics available by 2020.
Expert view: Engineered antibodies: semi-rational design approach for faster optimisation
A significant hurdle in optimising antibody therapeutics is the screening of successive rounds of large libraries of mutant variants in order to recognise the ideal candidate.
Expert view: Call to action: establishing the protein-binding properties of oligonucleotides
The number of oligonucleotide-based platforms on the market is constantly increasing and has led to the emergence of innovative nucleic acid-based therapeutic modalities such as CRISPR-Cas, sgRNAs or mRNAs.
Expert view: Clarification of cell cultures without centrifugation
Monoclonal antibodies are used in a wide range of applications, such as basic research, biopharmaceutical development and in vitro diagnostics.
